Does Rallies show Form 4 insider transactions for ONCY?

Yes. Rallies tracks ONCY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ONCY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ONCY. It does not provide personalized investment advice.

ONCY (Oncolytics Biotech, Inc. Common Shares) Stock Analysis - Insider Trades

Oncolytics Biotech, Inc. Common Shares (ONCY) is a publicly traded Healthcare sector company. As of May 21, 2026, ONCY trades at $0.84 with a market cap of $92.91M and a P/E ratio of -2.77. ONCY moved +6.72% today. Year to date, ONCY is -15.03%; over the trailing twelve months it is +90.83%. Its 52-week range spans $0.33 to $1.53. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces ONCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ONCY stock inside the company?

Recent ONCY insider activity includes Kelly Jared bought 5.05K, Parsons James T. bought 10.00K, Kelly Jared bought 29.50K, Look Kirk bought 12.00K, and Pisano Wayne bought 30.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ONCY Key Metrics

Key financial metrics for ONCY
Metric	Value
Price	$0.84
Market Cap	$92.91M
P/E Ratio	-2.77
EPS	$-0.30
Dividend Yield	0.00%
52-Week High	$1.53
52-Week Low	$0.33
Volume	147
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-28.76M
Gross Margin	0.00%

Recent ONCY Insider Trades

Kelly Jared bought 5.05K (~$4.85K) on Mar 12, 2026.
Parsons James T. bought 10.00K (~$10.30K) on Mar 11, 2026.
Kelly Jared bought 29.50K (~$24.84K) on Feb 12, 2026.
Look Kirk bought 12.00K (~$10.10K) on Feb 12, 2026.
Pisano Wayne bought 30.00K (~$25.34K) on Feb 12, 2026.

Latest ONCY News

Oncolytics' Pelareorep Yields 19.5-Month Median Response in KRAS-Mutant MSS Colorectal Cancer — May 4, 2026
FDA Aligns Oncolytics on Randomized Pelareorep Trial Showing 82% 12-Month Survival — Apr 27, 2026
Oncolytics Completes March 31 Nevada Domestication, Moves Headquarters to San Diego — Apr 1, 2026
Oncolytics Biotech to Present Data Showing 62% ORR and 7.5-Month PFS Boost — Mar 19, 2026
Oncolytics Biotech Launches Phase 2 REO 033 Trial Targeting $3-5 B Colorectal Cancer Market — Mar 5, 2026

ONCY Analyst Consensus

4 analysts cover ONCY: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.

Common questions about ONCY

Who is trading ONCY stock inside the company?: Recent ONCY insider activity includes Kelly Jared bought 5.05K, Parsons James T. bought 10.00K, Kelly Jared bought 29.50K, Look Kirk bought 12.00K, and Pisano Wayne bought 30.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ONCY?: Yes. Rallies tracks ONCY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ONCY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ONCY. It does not provide personalized investment advice.